

*Together, we can provide better health
to people everywhere.*

TOP STORIES

Life Science Summit III features Discovery Fund awardees

Organized by WBBA, the Governor's Life Science Summit III last week attracted more than 250 stakeholders from Washington's life sciences community. News of the life sciences industry was reported from the four corners of Washington, strategies to continue to move forward on recommendations from the comprehensive strategy presented at last year's Summit were discussed, and **Governor Christine Gregoire** pledged her ongoing support.

The **Life Sciences Discovery Fund Authority** awarded its first round of grants last month, and several of the recipients were on hand to describe their research. LSDFA, created by the Legislature in 2004, promotes life sciences research and innovations to enhance the competitive position of Washington while improving the quality and delivery of health care. The Discovery Fund awardees and projects are: **Daniel T. Chiu, University of Washington** (monitoring breast cancer metastasis and treatment efficacy); **David Flum, UW** (surgical care and outcomes assessment program); **William Hagopian, Pacific Northwest Research Institute** (diabetes evaluation in Washington state); **Jeffrey Hummel, Qualis Health** (applying health information technology to improve medication management); **Cornelius Ivory, Washington State University** (rapid fingerprinting of cardiac biomarkers); **David Newell, Swedish Medical Center** (intracranial and intraventricular hemorrhage with ultrasound enhanced thrombolysis). For-profit companies have partnered with the aforementioned researchers; contracts are currently being signed and those companies will be listed in a future NewsFacts. Special thanks to the Summit lead sponsors: **Amgen, Moss Adams, PhRMA, Port of Seattle, Seattle Children's Hospital Research Institute, and Swedish Medical Center.**

WSU President Elson Floyd to keynote WBBA Annual Meeting



Dr. Elson Floyd, the recently appointed President of **Washington State University (WSU)**, will be the keynote speaker of the WBBA Annual Meeting the morning of Tuesday, Oct. 30. A native of Henderson, NC, Floyd holds a BA, an ME and a PhD, all from the University of North Carolina at Chapel Hill. He will discuss the statewide vision of WSU, Washington's land grant university, with regard to global health, the life sciences and economic development. Founded in 1890, WSU has a diverse population of more than

23,000 students in 10 colleges and graduate school and campuses in Pullman, Spokane, the Tri-Cities and Vancouver. WSU has strengths across the life sciences, including advanced plant science, zoonotic disease, diabetes, sleep research, cancer therapies and others, with spin-off bioscience companies located around the state working in areas as diverse as animal science, reproductive medicine and oncology. In addition to hearing President Floyd's insights, a progress report on the comprehensive life sciences strategy will be reviewed and priorities for the coming year will be discussed at the Annual Meeting.

When/Where: Oct. 30/Seattle Sheraton Hotel

Time: Registration/Coffee: 7 am; Breakfast: 7:45 am, adjourn at 9 am.

Cost: \$80 members/\$175 for non-members (individual); Table for 10: \$1,000

Come to Life Sciences Research Week activities in November

Mark your calendar for Life Sciences Research Week, Nov. 3 through 11. Activities will include a symposium on the frontiers of research at Town Hall, 8 - 11am on Thursday, Nov. 8, and a special Life Sciences Research Weekend for families at the Pacific Science Center, Nov. 8 through 11. Life Sciences Research Week is organized

OCTOBER 3, 2007

WBBA PLATINUM LEADERS

Amgen
DLA Piper US LLP
Gilead Sciences
Heller Erhman LLP
Kirkpatrick & Lockhart
Preston Gates Ellis LLP
Lane Powell PC
Merck & Co., Inc.
Moss Adams LLP
Orrick, Herrington
& Sutcliffe, LLP
Perkins Coie LLP
University of Washington
Wells Fargo Insurance Services

WBBA GOLD LEADERS

Airgas Specialty Gas Division
Alexandria Real Estate Equities, Inc.
Battelle Pacific Northwest Division
Benaroya Research Institute
Bill & Melinda Gates Foundation
BNBuilders, Inc.
Cardiac Science, Inc.
Darby & Darby PC
Davis Wright Tremaine LLP
Dendreon Corporation
Dorsey & Whitney LLP
Ernst & Young LLP
Fred Hutchinson Cancer
Research Center
Hillis Clark Martin & Peterson
Inland Northwest Health Services
Institute for Systems Biology
KPMG LLP
Lease Crutcher Lewis
McKinstry
Microsoft
Mortenson Construction
NBBJ
Parker | Smith | Feek
Philips Ultrasound
Premera Blue Cross
PricewaterhouseCoopers LLP
Seattle Children's Hospital Research
Institute
Sellen Construction
Silicon Valley Bank
Skanska USA Building, Inc.
SonoSite
Swedish Research Division at
Swedish Health Services
Townsend and Townsend
and Crew LLC
Turner Construction Co.
Vulcan Inc.
Washington State University
Woodcock Washburn LLP
ZymoGenetics, Inc.

WBBA OFFICERS

Chair
James Gore
Pacific Northwest Research Institute

Immediate Past Chair
Bruce Montgomery, MD
Gilead Sciences

Secretary
Kevin Kelly
Heller Ehrman LLP

Treasurer
Erick Rabins
Allied Minds, Inc.

President
Jack Faris, PhD
WBBA

by the **Washington Biotechnology & Biomedical Association** and the **Northwest Association for Biomedical Research** with the participation and support of **Benaroya Research Institute at Virginia Mason** and other research institutions in our community. See the bottom of page 7 of this NewsFacts for more information and to find out how *you* can volunteer to be a part of Life Sciences Research Week 2007.



Jim Gore named Vice President of PNRI

Jim Gore has joined the **Pacific Northwest Research Institute (PNRI)** as the organization's first Vice President. "With an impressive track record in the supervision of nonprofit and biomedical operations, Jim has the proven knowledge and expertise to be an invaluable partner as we guide PNRI to new levels of scientific discovery and clinical application – with his help, we are closer than ever to conquering diabetes," said **Paul Robertson, MD**, President and Scientific Director. Gore's first charge as VP will be to enhance development efforts at PNRI and assist in the direction of the Warren G. Magnuson Congress for a Global

Diabetes Alliance, which PNRI convenes Oct. 21 - 23 in Seattle. The Congress aims to foster innovative partnerships to advance improvements in the prevention, treatment and cure of diabetes. The Congress will also serve as catalyst for the creation of an international alliance dedicated to raising money to fund clinical research of diabetes in underserved populations worldwide. Prior to joining PNRI, Gore served as COO for Seattle Biomedical Research Institute (SBRI) and prior to that he was with Pacific Medical Center. Jim Gore is currently Chairman of the WBBA Board of Directors.

Opening the door to balance – EAP WBBA benefit

Problems are a normal part of life, and most of the time we handle the issues or transitions we experience effectively and without help. At other times, problems take a toll on our well-being, relationships or happiness. Our lives get out of whack. It's at times like these that contacting your Employee Assistance Program (EAP) can open the door to balance for you and your family. Many WBBA core member companies contract with **Wellspring Family Services EAP** through the WBBA Benefits Program to provide confidential assessment and referral services. The EAP is a resource for employees and their eligible dependents to contact when they are experiencing emotional or behavioral concerns which may be affecting the quality of their lives. This includes three sessions for counseling assessment and counseling services, legal, financial and eldercare referrals. There is no charge to employees of WBBA member companies which have signed up for this as part of the WBBA employee benefit program. For more information call 1-800-553-7798 or access Wellspring's website at www.wfseap.org. Your username is your company name. For questions, please contact **Betsy Sullivan, MA**, at bsullivan@wfseap.org. To sign up for this benefit, contact your broker or **Bryan Marsh** at **Wells Fargo Insurance Services**, bryan_marshall@wellsfargo.com.




Wellspring Family Services EAP
It's to Your Benefit

Apologies for an error

An article in the Sept. 5 issue of the NewsFacts invited WBBA members to an Oct. 18 gala in San Francisco honoring **Dr. John Martin**, President & CEO of **Gilead Sciences**. NewsFacts erroneously reported that Martin was the Invest Northwest keynote speaker in earlier this year. The keynote from Gilead was **John Milligan**, not John Martin. Many apologies for the error. RSVPs are still being taken for the Oct. 18 gala. Please contact or email Grazia Bennett, gbennett@iie.org or visit: <http://www.iiesf.org/new/calendar/calendar-gala.htm>.

Philip Green III is the Inventor of Year – help celebrate Oct. 10

UW Medicine, Frazier Healthcare Ventures, the Washington Research Foundation, and local biotechnology, medical device and venture capital industries invite you to celebrate the achievements of **Philip Green III, PhD** as he receives the **2007 Inventor of the Year Award**. Green – a UW Professor of Genome Sciences, Adjunct Professor of Computer Science and Engineering and a Howard Hughes Medical Institute Investigator – has had a profound impact on the development of genome analysis. His software has made the sequencing of the three billion pairs in the human genome possible and represents the most important technical advance in DNA sequencing of the 1990s. To be held Wednesday, October 10, 6 – 8 pm at the Seattle Asian Art Museum at Volunteer Park, there is no charge for this reception but please pre-register by contacting **Barbara Mahoney** at 206-534-7738, bmahoney@u.washington.edu or online: <https://catalysttools.washington.edu/survey/bmahoney/39781>.



Local researchers win \$500,000 MacArthur "Genius Awards"

Yoky Matsuoka of the **University of Washington** and **Mark Roth** of the **Fred Hutchinson Cancer Research Center** were recently honored by the prestigious MacArthur Foundation for their "creativity, originality and potential to make important contributions in the future." Roth, a biologist at the Hutch whose studies of suspended animation may result

in new treatments for trauma, heart attack or stroke, and Matsuoka, who combines a knowledge of robotics with the study of neurology to invent thought-controlled prosthetic limbs, will join 22 other "genius" fellows this year awarded \$500,000 each by the MacArthur Foundation. Roth plans to take several months to mull his options for using the grant. Matsuoka hasn't decided yet how to use the no-strings-attached grant, but she's considering either launching a company to develop her ideas into products, or writing a book to encourage women to go into science and engineering.

WELCOME NEW MEMBERS

NEW GOLD LEADER MEMBER: [Mortenson Construction](#). Mortenson Construction provides services for every aspect of a project's lifespan, from the initial identification of a business requirement through management and/or ownership of the resulting facility. Mortenson is experienced in every possible delivery method, but regardless of contract type, Mortenson is a builder. The company takes responsibility for their role, actively managing every component of the process. Mortenson has in-house expertise in every aspect of facility development. Sustainable building is an emphasis of Mortenson. In 2006, two of the Seattle office's projects were certified by the US Green Building Council as LEED Gold. For more information, please contact **Rodger Benson**, Director of Project Management, 425-895-9000 or Rodger.benson@mortenson.com.



ABODA Corporate Housing, recognized as a leader in the corporate housing industry for more than 19 years, has joined WBBA and offers a discount to members. ABODA offers comfortable, quality interim suites that come fully furnished and equipped with appliances, utilities, and bi-weekly housekeeping. Additionally, ABODA specializes in real estate, property management, furniture rental, housekeeping, and carpet cleaning. Their expertise is facilitating unique housing solutions in a wide variety of locations for each priority: being close to work, a specific school district, or downtown area for any length of stay. ABODA provides excellent service and solutions for organizational growth in the biotechnology and medical device fields. To find out more about an exclusive offering of 10 percent off all services to WBBA members, contact **Kari Hamilton** at 425-602-5560 or kari.hamilton@abodach.com.

Aspen MedTech, Inc. was formed mid 2007 to identify an unmet clinical need in a growing market, invent or license relevant medical device technology, and start a new company to develop and commercialize the solution. The founder and partners at Aspen MedTech have decades of experience developing and commercializing new medical technologies across a range of clinical disciplines. Together they formed Seattle Medical Technologies, an insulin delivery company funded by Three Arch Partners and Frazier Healthcare ventures. In addition to Seattle Medical, the team has collectively been involved in founding or building more than 10 early stage medical device companies. In total, these companies have raised more than \$500 million in venture capital, and \$300 million in public funding. Initial funding for Aspen MedTech was provided by Three Arch partners and Prospect Venture Partners. For more information, visit <http://www.aspenmedtech.com>.

QPS - (Quest Pharmaceutical Services) is a private-owned GLP-compliant CRO supporting discovery, preclinical, and early clinical development. Since their inception in 1995, QPS has been providing Bioanalysis (LC/MS/MS, ELISA, Immunogenicity, and Hybridization-ELISA), DMPK (PK, Quantitative Whole Body Autoradiography, Micro-autoradiography, Protein Binding, In vivo/in vitro Drug Metabolism, Mass Balance, Metabolite Identification), Biomarker (Protein markers, Cell-based markers, Genetic markers, SNP genotyping, Gene expression profiling) for companies worldwide. For more information contact **Sally Hayes** at 425-898-0258 or sally.hayes@questpharm.com

LIFE SCIENCE NEWS

Angiotech Pharmaceuticals (NASDAQ: ANPI, TSX: ANP) received CE Mark approval to begin marketing additional diameters of its Quill™ Self-Retaining System (SRS) Polydioxanone (PDO) product line in Europe. The Quill SRD PDO is a longer-lasting absorbable suture used for deeper tissue closures. With CE Mark approval the additional 3-0 and 4-0 sizes, Angiotech now offers diameters ranging from sizes 2 to 4-0 in Europe. In other news, Angiotech received a favorable decision on Sept. 10 from the New Zealand Intellectual Property Office regarding an attempt by Johnson & Johnson's subsidiary, Conor Medsystems to revoke Angiotech's New Zealand Patent 523799, which pertains to compositions comprising a polymer and paclitaxel, as well as, generally, to paclitaxel-eluting stents. "Consistent with virtually all international rulings to date, this decision further corroborates the strength of our IP and our ability to defend our global patent portfolio," said **Dr. William Hunter**, Angiotech President and CEO.

Bill and Melinda Gates Foundation's President of Global Health, **Dr. Tadataka "Tachi" Yamada**, will be recognized by Queen Elizabeth II with honorary knighthood. He is being honored for work done in his previous position as Chairman of R&D in the UK for GlaxoSmithKline from 2000 – 2006. The honor, "Knight Commander of the Order of the

British Empire" is presented to those who have made an important contribution to relations between their country and Britain. Bill Gates, several former US presidents and director Steven Spielberg have also received the award.

Cardiac Science Corporation (Nasdaq: CSCX) applauded the mass training of 1,838 teachers and other lay rescuers from the Pittsburgh school district in cardiopulmonary resuscitation with an automated external defibrillator (AED). Cardiac Science is the preferred provider of AEDs to Pittsburgh United for Life Saving Emergencies (PULSE), a local public access defibrillation program. The training was sponsored by PULSE in partnership with Cardiac Science and Parent Heartwatch, a network of parents dedicated to reducing the effects of sudden cardiac arrest in children.

CellCyte Genetics (OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV) signed a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation of Cleveland, OH. The collaboration will investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds. CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart.

CG Therapeutics has named **Christopher Henney, PhD, DSc** -- who co-founded three of Seattle's biggest biotech companies, Immunex, ICOS Corp. and Dendreon -- as Chairman of the Board. Henney's role is to help the startup with venture funding and corporate partnerships. CG Therapeutics plans to complete a Series A Financing to fund its Phase II clinical study of CG201 in non-small cell lung cancer and colorectal cancer.

Cell Therapeutics, Inc. (Nasdaq and MTAX: CTIC) announced that **Richard L. Love** has joined its board of directors. Love was the Chairman of the Board for Systems Medicine, which was recently acquired by CTI. Systems Medicine, which works with the Translation Genomics Institute ("TGen") in Arizona, uses the latest drug development technology to discover weak spots in a disease's genetic make-up and identify which drugs will be most effective at treating the disease. He has worked in the industry for more than 40 years. In other news, CTI has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC). The trial, known as PGT307, will focus on women with pre-menopausal estrogen. XYOTAX (TM) (paclitaxel poliglumex) will be studied in combination with carboplatin versus paclitaxel/carboplatin in female NSCLC patients with performance status of 0, 1, or 2. CTI also reported a Phase III trial, known as PIX303, of pixantrone for patients with indolent non-Hodgkin's lymphoma (NHL) who have relapsed following first-line therapy. For more information, visit <http://www.ctiseattle.com>.

Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9. The companies anticipate launching a CE-marked test in Europe in 2009 followed by regulatory filing for U.S. approval in 2010. Under the terms of the agreement, Epigenomics will receive an up-front fee, milestone payments and royalties on product sales. The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.

Fred Hutchinson Cancer Research Center scientists have discovered that fetal cells that persist in a woman's body long after pregnancy – a common occurrence known in scientific circles as fetal microchimerism – may in some cases reduce the woman's risk of breast cancer. The findings, published in the Oct. 1 issue of *Cancer Research*, add to the Jekyll and Hyde characteristics of fetal microchimerism, or FMc, which has been found to be both detrimental and beneficial to women's health. **V.K. Gadi, MD, PhD** and **J. Lee Nelson, MD** concluded that FMc may contribute to reduction of breast cancer based on the hypothesis that residual fetal cells may provide immune surveillance of malignant cells in the mother. They caution that further studies are needed to confirm the theory. The research was funded by the National Institutes of Health and **Amgen Inc.**

Gilead Sciences, Inc. (Nasdaq: GILD) announced that data from a Phase IIb study (DAR-201) of darusentan, an investigational treatment for resistant hypertension, were published in the October 2007 edition of the *Journal of Clinical Hypertension*. In this study, darusentan was evaluated as an add-on antihypertensive treatment in patients who had not achieved goal blood pressure while being treated with full doses of three or more antihypertensive medications, including a diuretic. Gilead is currently conducting two follow-on, pivotal Phase III clinical trials in resistant hypertension: DORADO (DAR-311) and DORADO-AC (DAR-312).

Healionics Corporation, an affiliate of **Ratner Biomedical Group**, announced a partnership with Strategic Applications Inc (SAI) which makes specialty catheter and infusion devices. The deal will fund a catheter cuff study that compares Healionics STARcuff to other leading catheter cuffs on the market. It also includes an exclusive supply and

distribution option which will give SAI the right to distribute STARcuff in specific global markets. In other news, Healionics did very well at the second annual Zino Zillionaire Investment Forum where 28 entrepreneurs from a variety of industries competed for \$150,000 in prize money and the attention of Seattle angel investors. **Robert Brown**, President and CEO of Healionics impressed the group enough to win first place for best technology investment. The UW spin-out, looking to raise \$1.5 million, is developing biomaterials for use in tissue regeneration.

Helix BioMedix (OTCBB: HXBM) announced an agreement through which Degussa Goldschmidt Personal Care will become Helix BioMedix's exclusive marketing partner for its Combikine™ and Replikine™ class of anti-aging peptides in addition to other selected peptides targeted at skin care applications. In other news, **Jack Clifford** has been named to the board of directors of Helix BioMedix. "Jack brings extensive experience and industry relationships at an important point in the company's development," commented **R. Stephen Beatty**, President and CEO. "His past expertise with negotiating license agreements for both consumer and pharmaceutical peptide applications with companies such as Neutrogena, Merck and C.R. Bard, will prove invaluable as we continue our efforts to further commercialize our peptides and develop our pharmaceutical program." Clifford recently served as Chairman, President and CEO of Procyte Corporation, a developer of skin, hair and wound care products for dermatological and surgical applications.

Ikaria Holdings, Inc. announced that **Ralf Roskamp, MD**, has been appointed Executive Vice President of Research and Development, reporting to Chairman and CEO **David Shaw**. Roskamp most recently was EVP of R&D at Kos Pharmaceuticals and was previously with Aventis Pharmaceuticals. Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations that improve the lives of patients and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI.

IsoRay Medical™, Inc., a subsidiary of IsoRay, Inc. (collectively IsoRay) (AMEX:ISR), signed a letter of intent between IsoRay and International Brachytherapy s.a. (IBt), manufacturer/distributor of brachytherapy products based in Seneffe, Belgium, to form a global strategic alliance focusing on worldwide market expansion of brachytherapy solutions in the treatment of prostate cancer and other malignant tissue cancers. A major element of the proposed alliance is the future marketing of IsoRay's proprietary Proxcelan™ Cesium-131 brachytherapy seeds and Iodine-125 brachytherapy seeds in Russia. It includes planned distribution in 19 European countries using IBt's established distribution channels.

MDS Capital Corp. announced investment team promotions and has changed its name to **Lumira Capital Corp.** as of Sep 18, 2007. The name change to Lumira Capital is the final part of a strategic repositioning to enable the firm to build on its strength as a leading North American investor in biopharmaceutical and medical device companies. The company's new web site is <http://www.lumiracapital.com>.

Nanogen, Inc. (Nasdaq: NGEN) has been granted US Patent No. 7,252,940, titled "Abasic site endonuclease assay" from the US Patent and Trademark Office. The technology described in the patent extends the underlying proprietary real-time PCR technology used in the Company's MGB Alert® products to a new product offering that has been commercialized as research reagents for use in replication validation following genome wide scanning in pharmaceutical and biotechnology industry labs. This technology may also be used for genetic analysis in multiplex formats of complex genetic diseases.

Nastech Pharmaceutical Company began a Phase II clinical trial evaluating its rapid-acting Insulin Nasal Spray in approximately 20 patients with type 2 diabetes. The study is a randomized, crossover study evaluating formulations of Insulin Nasal Spray as compared to NovoLog(R) insulin aspart (rDNA origin), an approved injectable insulin, on post-meal glycemic control. Data from Nastech's earlier studies showed that the Insulin Nasal Spray achieved faster time to maximum plasma levels than NovoLog injection and Exubera(R) (insulin human [rDNA origin]) Inhalation Powder in healthy subjects. Additionally, the formulations tested did not show any clinically significant hypoglycemia. The Phase II study design will evaluate different doses of Nastech's Insulin Nasal Spray compared to NovoLog and a placebo.

Pacific Northwest National Laboratory (<http://www.pnl.gov>) received two forms of national recognition in September. The Laboratory placed 54th out of 500 companies in a national ranking by InformationWeek of America's most innovative companies that use information technology. In a separate honor, Laboratory staff **Gary Spanner** and **Richard Fowler** were selected for a national Tibbetts award for developing a free, national electronic alerting service that keeps subscribers aware of current federal funding opportunities from the Small Business Innovation and Small Business Technology Transfer programs. More at <http://www.tibbettsawards.org/>.

Poniard Pharmaceuticals, Inc. was granted fast track designation by the FDA for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC). Picoplatin is being studied in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is evaluating overall survival as the primary endpoint and is being conducted under a Special Protocol Assessment (SPA) agreement

with the FDA. Yesterday, Poniard presented updated data from its Phase 2 SCLC trial at the World Conference on Lung Cancer, which confirmed and extended a median overall survival of 27 weeks, comparing favorably to a median survival of approximately 17 to 22 weeks for patients who receive other second-line chemotherapy according to the 2007 National Comprehensive Cancer Network practice guidelines.

ReachBio LLC announced the official opening of its business operations. The company provides specialized contract assay and contract research services using in vitro and in vivo stem cell and progenitor cell assays to biopharma, biotechnology, agri-chemical, and other related industries. In particular, the company will draw on their experience in clinical and industrial stem cell and progenitor cell biology to offer services for evaluating the toxic, inhibitory or stimulatory effects of compounds on hematopoietic and non-hematopoietic cells. The founding members of ReachBio are all former long-time scientists, managers and executives of StemCell Technologies, Inc., a Canadian company that provides products and services to the stem cell research industry.

Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) announced that its Phase III trial of TOCOSOL(R) Paclitaxel in women with metastatic breast cancer did not meet its primary endpoint of non-inferiority on objective response rate (ORR) when compared to the Taxol(R) control arm. Trial results showed the ORR for TOCOSOL Paclitaxel was 37 percent versus 45 percent for Taxol (p value = 0.085). The outcome of this trial does not support the submission of a New Drug Application. Sonus CEO & President **Michael A. Martino** said, "We are profoundly surprised and disappointed that TOCOSOL Paclitaxel did not achieve the primary endpoint of this pivotal trial, particularly given the efficacy and safety results from previous clinical studies of our drug. Given these results, we expect Bayer Schering will exercise its right to terminate our agreement. In the coming weeks, Sonus will further evaluate the data and make decisions about the future of TOCOSOL Paclitaxel and other programs. Our primary goal remains to maximize shareholder value, and we are actively evaluating all alternative ways to achieve that goal."

Spiration, Inc. reported on Sept. 26 that the first patients will soon begin using its intra-bronchial valve system on an experimental basis. The product is designed to ease breathing in people with severe emphysema, redirecting airflow from diseased portions of the lung to healthier areas with no need for major surgery. The trials will enroll up to 500 patients at up to 40 sites in the US.

Trubion Pharmaceuticals announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis. The trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. "We are pleased that the positive results of this study confirm the activity seen in our prior study and demonstrate that TRU-015 can meaningfully improve disease activity in patients with RA," said **Peter Thompson, MD**, President, CEO and Chairman of Trubion, saying an additional study will probably be conducted before moving to a Phase III clinical trial.

VLST Corp announced the appointments of **Consuelo M. Blosch, MD** as VP of Clinical & Regulatory and **Dan Allison, PhD**, as Senior Director of Therapeutic Design. Blosch joins VLST from the **Benaroya Research Institute at Virginia Mason (BRI)**, where she was Administrative Director of the BRI Clinical Research Program. Prior to BRI, Blosch held positions at Immunex Corp. and NPS Pharmaceuticals. Allison joins VLST from ICOS, where he most recently served as Senior Director, Production Devel. with responsibility for engineering antibodies and other proteins used in clinical studies and directing the development of microbial and mammalian expression systems used to produce those proteins.

UPCOMING EVENTS

- Oct. 23** **Buddy Ratner** on "Rebuilding the Baby Boomer: Replacement Parts for the 21st Century", 7 – 9 pm UW School of Engineering, Kane Hall, UW Seattle. http://www.washington.edu/alumni/clubs/eng/2007lectures_1023.html
- Oct. 18** **Dr. John Martin of Gilead** honored in SF. Visit <http://www.iiesf.org/new/calendar/calendar-gala.htm>
- Oct. 23 - 24** **Warren G. Magnuson Congress for a Global Diabetes Alliance**, Seattle, register online at: <http://www.pnri.org/news/2007/magnuson/>.
- Oct. 25** **UW Science & Engineering Job Fair at the HUB**, <http://www.uwseba.org/career-fair-companies.html>
- Oct. 30** **WBBA Annual Meeting**, breakfast, Seattle featuring **Dr. Elson Floyd**, President of **Washington State University**. **Sponsorships available**; contact pamlove@washbio.org
- Nov. 8** **Life Sciences Research Week Forum**, Town Hall, 8 – 11 am.
- Nov. 8 – 11** **Life Sciences Research Weekend at Pacific Science Center**.
- Nov. 14 -17** **MEDICA – Dusseldorf, Germany**. Join the State of WA and access MEDICA at a lower cost and meet partners, distributors and buyers from around the world. Contact **June Chino** junec@cted.wa.gov or 206-256-6144.

Jan. 22 **WBBA Life Science Day in Olympia.** Free to WBBA members, sponsorships available, email patti@washbio.org
 Mar. 18-19, '08 **Invest Northwest 2008**, Bell Harbor International Conference Center, Seattle.

ADVERTISEMENTS & MARKETING OPPORTUNITIES

Sponsor BioEvolution 2008! Promote your company and Washington's biotechnology, medical device and healthcare industry, then sponsor the WA BioEvolution 2008 poster/brochure that will be used to promote our state's industry regionally and nationally in conjunction with the BIO 2008 International Conference in June, along with other WBBA events throughout the year. WA BioEvolution poster is a one-of-a-kind poster that illustrates the "technology origins" of more than 250 biotechnology and medical device firms in Washington. For info, visit: <http://www.wabio.com/evolution/> or call InfoResource, owner and publisher of WaBio.com, 206-937-3620 or e-mail: Sponsor@InfoResource.org.



Looking for the Right Candidate? Need to Recruit Nationally? Advertise with the WaBio.com national network of state-based biotechnology web sites that represent more than 3,500 biotechnology and medical device companies, non-profit research institutions, universities and supporting service sector companies across the US. Cost effectively target your employee recruitment by state, region or nationwide for the same low rate. WBBA members receive a 15% discount off the standard advertising rate. WaBio.com job postings are \$175/mo. for WBBA members and you can now place your job postings with any or all of our affiliate state sites at "no additional charge." To learn more, access http://www.wabio.com/ad/ad_jobs.htm or call 206-937-3620. Recruit better through [WaBio.com](http://www.WaBio.com).

AMERICAN PACIFIC RELOCATION NETWORK is a perfect solution to address the needs of WBBA member corporations looking for an alternative choice in relocation support providers and services for new and transferring employees. Whether a corporation moves one or 200 employees, there are many reasons to utilize relocation services to ensure employees have a productive start in their new location. Our Service partners are comprised of the best local and regional relocation service suppliers in the industry and ensure quality options to choose from. For assistance or more information, call 800-426-1442 ext.116 or e-mail at info@ampacnetwork.com



Get ahead of the competition! As an internet services company, **The Next Phase (TNP)** provides its medtech and biotech clients A Better Way through its online MedIntelliBase Custom Alerts and MIB MarketTracks. MedIntelliBase empowers its clients with up-to-the-minute intelligence pushed to them via email on breaking clinical research, emerging technologies, market competitors, and industry events customized to each client's needs. These new services are built upon TNP's experience as a consultancy, providing market research and business development services to the medical device and biotech industries since 1995. Contact TNP to learn more about what MedIntelliBase Alerts and MarketTracks can do to keep you ahead of your competition: <http://www.MedIntelliBase.com> – ABetterWay@MedIntelliBase.com - 1-425-869-8724.



Witt Company, a WBBA Business Solutions Partner, is available to help both core and associate members with efficient solutions for **document imaging and management**. The days of paper files, manual copying and slow fax machines are outdated! Witt Company uniquely combines digital technology with responsive technical support. From production to destruction and all the cycles in between, Witt Co. provides solutions to your document imaging and management needs. Ask about the WBBA member discount - create efficiencies - reduce costs - help meet regulatory/reporting requirements! Contact **Carson Lemmen** at clemmen@witt-company.com or 206-930-2328 or visit <http://www.witt-company.com>.

Life Science Research Week 2007 – How to Get Involved!!

Share the exciting and creative science that is going on at your company or institution by participating in Life Sciences Research Weekend at the Pacific Science Center. This is your opportunity to engage the public, enhance their understanding and appreciation of life sciences research across the state, and acquaint them with career opportunities in the life sciences.



Co-organized by NWABR and the WBBA, Life Sciences Research Weekend, at the Pacific Science Center (PSC) is one of two elements of Research Week. Life Sciences research from around the state will be showcased:

demonstrations, activity tables, and informal lectures given to visitors waiting in lines for the IMAX, planetarium, and Butterfly house. Demos will feature interactive teaching using several elements: 1) SimMan simulation mannequin sponsored by Renton Technical College, 2) rodent nest building by veterinarians from VA Puget Sound Health Care Systems and 3) a journey into the brain by Eric Chudler of UW Biomedical Engineering. Examples of activity tables include student projects by Biotech Expo students, "reverse operation" game placing medical devices into a skeleton (UW Biomedical Engineering), Arkitek studios science animation, virtual SnowWorld, which promotes healing in burn patients (UW Medicine), and others.



How you can help: Two of three "line lecturer" positions are staffed, but we still need someone(s) to speak to the audience in the planetarium wait line. We are seeking additional individuals or teams (from companies, departments, or labs) to provide interactive exhibits/displays to engage children and their parents.

Exhibitor Specifics: Institution displays are needed that can be up all four days (Thursday - Sunday, Nov. 8 -11th) with a hands-on, interactive component that your people can staff approximately four hours each day, 10 am to 2 pm. Recruiting 8 volunteers for 2 hour shifts would provide the PSC visitors with an opportunity to meet "real scientists". You will receive visibility and your volunteers will receive parking passes and free admission to the PSC.

Sign up today! Contact **Reitha Weeks** at weeks@nwabr.org or **Jennifer Wroblewski** at jenniferw@nwabr.org to register your participation or receive more information.

Call for Sponsorships!

October 30, 2007 WBBA ANNUAL MEETING BREAKFAST

Associate Members: Increase your visibility at the second-largest WBBA event of the year. Contact Pam Love at 206-732-6705 or pamlove@washbio.org to secure your Premier (\$3,000), Display (\$2,000) or Table Host (\$1,000) sponsorship today!

Individual and Sponsorship Registration Open Online at <http://www.washbio.org>

Thanks to the Premium Sponsors who have committed already:

Seattle Children's Hospital Research Institute, Seed IP Law Group, University of Washington, Wells Fargo Insurance Services
Display Sponsors: SonoSite and Natestch Pharmaceuticals

WBBA NEWS FACTS

WASHINGTON BIOTECHNOLOGY
& BIOMEDICAL ASSOCIATION

*Together, we can provide better health
to people everywhere.*

The Washington Biotechnology & Biomedical Association (WBBA) is working with leaders across the state to implement a comprehensive bioscience strategy for Washington's future. *NewsFacts* is issued monthly except for December, depending on news volume, and sent to more than 1500 subscribers as a benefit of WBBA membership.

Send NEWS to Pam Love at pamlove@washbio.org. To UNSUBSCRIBE, email: kathleen@washbio.org with "NewsFacts unsubscribe" as the subject line. For more information, contact WBBA. Phone 206-732-6700.

2324 Eastlake Ave. E., Suite 500
Seattle, WA 98102 www.wabio.com

© 2007 Washington Biotechnology & Biomedical Association. All rights reserved.